Alloy Therapeutics Raises $1 billion Series E
Alloy Therapeutics raised $1B in Series E financing. Alloy Therapeutics announced a Series E round. The new capital is framed around Expand AI-Driven Drug Development Platform - citybiz.
Series E$1 billionTotal tracked $1 billionUndisclosed HQ
What it does
Alloy Therapeutics announced a Series E round. The business sits in Healthcare & Life Sciences, where funded companies are using fresh capital to deepen product coverage, distribution, or operating capacity.
Traction
$40M. Management framed the new capital around Expand AI-Driven Drug Development Platform - citybiz.
Trend impact
MD-grade thesis held: available source material is not specific enough to support a non-generic investor-economist read without overclaiming.
Funding history
- April 15, 2026 · Series E · $1 billion · undisclosed investors
Products & services
- Healthcare & Life Sciences workflow monitoring tied to the funding announcement
- Customer-facing product described on the company website
- Operational tooling for healthcare & life sciences teams
- Data capture and reporting across core business processes
- Team expansion support funded by the latest round